Cell Sheet-Based Gene Therapy Market Report 2026

Cell Sheet-Based Gene Therapy Market Overview

• Cell Sheet-Based Gene Therapy market size has reached to $0.68 billion in 2025 • Expected to grow to $1.34 billion in 2030 at a compound annual growth rate (CAGR) of 14.6% • Growth Driver: The Rising Prevalence Of Chronic And Degenerative Diseases Fueling The Growth Of The Market Due To Increasing Demand For Regenerative Treatments • Market Trend: Advancing Autologous Gene-corrected Cell Sheet Therapies For Regenerative Medicine And Wound Healing • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cell Sheet-Based Gene Therapy Market?

Cell sheet-based gene therapy refers to a therapeutic approach that combines gene delivery with engineered layers of living cells to achieve localized and sustained gene expression at the target site. This method preserves cell-to-cell connections and extracellular matrix components, enhancing cell survival, integration, and functional stability after transplantation. It enables precise tissue regeneration and therapeutic gene activity while minimizing systemic exposure and unintended biological effects. The main cell-sheet types of cell sheet-based gene therapy include monolayer cell-sheet type, co-culture cell-sheet type, multilayered cell-sheet type, and other cell-sheet types. Monolayer cell-sheet type refers to a single layer of living cells engineered and cultured to deliver therapeutic genes to target tissues. These products use technologies such as cell sheet-based engineering techniques and gene delivery methods. They are derived from sources including autologous cells, allogenic cells, and stem-cell derived cells. They are applied across areas including oncology, ophthalmology, genetic disorders, cardiology, and other applications, and are used by end users including hospitals and clinics, research and academic institutions, biotechnology and pharmaceutical companies, and other end users.

What Is The Cell Sheet-Based Gene Therapy Market Growth Forecast?

The cell sheet-based gene therapy market size is expected to see rapid growth in the next few years. It will grow to $1.34 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to increasing demand for localized regenerative therapies, rising clinical trials in gene-modified cell therapies, expansion of oncology and cardiology applications, growing investments in advanced tissue engineering, increasing focus on precision regenerative medicine. Major trends in the forecast period include expansion of multilayered and co-culture cell sheet technologies, rising focus on localized gene expression therapies, growing integration of regenerative medicine approaches, increased use of stem-cell derived cell sheets, enhanced focus on tissue integration and longevity.

Global Cell Sheet-Based Gene Therapy Market Segmentation

1) By Cell-Sheet Type: Monolayer Cell-Sheet Type; Co-Culture Cell-Sheet Type; Multilayered Cell-Sheet Type; Other Cell-Sheet Types 2) By Technology Type: Cell Sheet-Based Engineering Techniques; Gene Delivery Methods 3) By Source Type: Autologous; Allogenic; Stem-Cell Derived 4) By Application: Oncology; Ophthalmology; Genetic Disorders; Cardiology; Other Applications 5) By End-User: Hospitals And Clinics; Research And Academic Institutions; Biotech And Pharma Companies; Other End-Users Subsegments: 1) By Monolayer Cell-Sheet Type: Cardiomyocyte Sheets; Epithelial Cell Sheets; Mesenchymal Stem Cell Sheets; Other Monolayer Cell Sheets 2) By Co-Culture Cell-Sheet Type: Fibroblast + Stem Cell Sheets; Endothelial + Smooth Muscle Cell Sheets; Other Co-Culture Combinations 3) By Multilayered Cell-Sheet Type: Triple-Layered Sheets; Double-Layered Sheets; Other Multilayered Configurations 4) By Other Cell-Sheet Types: Genetically Modified Cell Sheets; Hybrid Cell Sheets; Other Novel Or Experimental Sheets

What Is The Driver Of The Cell Sheet-Based Gene Therapy Market?

The rising prevalence of chronic and degenerative diseases is expected to drive growth in the cell sheet-based gene therapy market. Chronic and degenerative diseases are long-term conditions, including cardiovascular disorders, neurodegenerative diseases, diabetes, and genetic disorders, that progressively damage tissues and organs and require sustained therapeutic intervention. The prevalence of these conditions is increasing due to expanding aging populations and rising life expectancy across both developed and developing economies. Cell sheet-based gene therapy supports regenerative treatment approaches for chronic and degenerative diseases by enabling localized tissue repair and sustained gene delivery through layered living cell constructs, which can improve tissue integration and long-term therapeutic outcomes. For instance, in April 2025, according to the International Diabetes Federation (IDF), a Belgium-based non-profit organization, 589 million people worldwide were living with diabetes in 2024, a figure projected to rise to 853 million by 2050. Therefore, the rising prevalence of chronic and degenerative diseases is driving the growth of the cell sheet-based gene therapy industry.

Key Players In The Global Cell Sheet-Based Gene Therapy Market

Major companies operating in the cell sheet-based gene therapy market are Hitachi Ltd., Thermo Fisher Scientific, Fujifilm Cellular Dynamics Inc. (FCDI) (FUJIFILM Holdings Corporation), Lonza Group AG, teijin regenet co. ltd., Terumo Corporation, Nikon CeLL innovation Co. Ltd., Rohto Pharmaceutical Co. Ltd., BioBridge Global, AGC Biologics, Shibuya Corporation (Shibuya Kogyo Co. Ltd.), National Resilience Inc., Takara Bio Inc., Japan Tissue Engineering Co. Ltd. (J-TEC), Medipost Co. Ltd., Cell Therapies Pty Ltd, CellSeed Inc., SCTbio, Abeona Therapeutics Inc., Foundation ENEA Tech, Cyto-Facto Inc., ENCELL Co. Ltd.

Global Cell Sheet-Based Gene Therapy Market Trends and Insights

Major companies are operating in the cell sheet-based gene therapy market are focusing on developing innovative solutions such as, autologous gene-corrected cell sheet products to enhance regenerative medicine outcomes, treatment precision, and long-term tissue repair by combining engineered cells with scaffold-free sheet constructs for targeted gene delivery and wound healing. Autologous gene-corrected cell sheet products refer to therapies where a patient’s own cells are genetically modified ex vivo, expanded into sheet constructs that preserve cell-to-cell interactions and extracellular matrix integrity, and applied directly to damaged tissues to promote functional integration and durable therapeutic effects. For instance, in April 2025, Abeona Therapeutics Inc., a US-based biopharmaceutical company, received Food and Drug Administration (FDA), a US-based federal agency approval for zevaskyn (prademagene zamikeracel), designed to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Zevaskyn delivers the functional COL7A1 gene via genetically corrected cell sheets, promotes clinically meaningful wound healing and pain reduction with a single application, and supports sustained type VII collagen expression at wound sites—making it a breakthrough regenerative therapy and a model for future cell sheet-based gene therapy innovations.

What Are Latest Mergers And Acquisitions In The Cell Sheet-Based Gene Therapy Market?

In December 2023, Fondazione ENEA Tech e Biomedical, an Italy-based law foundation and investment firm, acquired Holostem Terapie Avanzate S.r.l. for an undisclosed amount. Through this acquisition, the foundation aims to preserve and enhance regenerative medicine capabilities and strengthen research and development in epithelial stem cell–based therapies within the advanced cell and gene therapy space. Holostem Terapie Avanzate S.r.l. is an Italy-based biotechnology company that specializes in developing and manufacturing cell sheet–based gene and cell therapy products, including epithelial stem cell medicinal products for treating rare and severe diseases.

Regional Insights

North America was the largest region in the cell sheet based gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cell Sheet-Based Gene Therapy Market?

The cell sheet-based gene therapy market consists of revenues earned by entities providing services such as targeted tissue regeneration, sustained gene delivery, and wound healing enhancement. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell sheet-based gene therapy market also includes sales of cell culture substrates, gene delivery vectors, processing tools, and supporting technologies used in the fabrication and application of therapeutic cell sheets. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cell Sheet-Based Gene Therapy Market Report 2026?

The cell sheet-based gene therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cell sheet-based gene therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.